Lumryz™ (sodium oxybate) – Expanded indication
October 17, 2024 - Avadel Pharmaceuticals announced the FDA approval of Lumryz (sodium oxybate) extended-release oral suspension, for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.
Download PDF
